News
IPSEF
185.93
NaN%
--
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Seeking Alpha · 09/01 13:16
ProQR a new buy at BoA on RNA-editing platform
Seeking Alpha · 08/20 13:49
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Seeking Alpha · 08/10 13:16
Ipsen to acquire Memo Therapeutics in deal worth over €700M
Seeking Alpha · 07/01 05:24
Ipsen S.A. reports Q1 results; reaffirms FY outlook
Seeking Alpha · 04/23 05:22
Regeneron: Fairly Valued Now After A Stellar Upswing
Seeking Alpha · 03/11 13:47
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Seeking Alpha · 03/05 19:41
Time To Take Profits On Gilead Sciences (Rating Downgrade)
Seeking Alpha · 02/20 19:24
Genfit adds $20M as Ipsen records strong sales for liver drug
Seeking Alpha · 02/12 18:52
Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
Seeking Alpha · 02/12 06:25
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Seeking Alpha · 01/14 11:57
What To Expect From Gilead In Q3 2025
Seeking Alpha · 10/24/2025 14:56
Ipsen S.A. reports Q3 results; upgrades FY outlook
Seeking Alpha · 10/22/2025 07:09
More
Webull provides a variety of real-time IPSEF stock news. You can receive the latest news about Ipsen Promesses through multiple platforms. This information may help you make smarter investment decisions.
About IPSEF
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.